Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 and up Men only

Testosterone injections to improve quality of life for men in best supportive care.

Official title: Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life

Run by Jules Bordet Institute · NCT07143279 · Data updated 2026-11-12

This pilot will test whether giving Sustanon 250 testosterone injections every 15 days can improve quality of life for men with low testosterone who are receiving best supportive (palliative) care.

More Palliative Care trials

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment20 (estimated)
SponsorJules Bordet Institute
Academic / other
Locations1 site (Brussels)
StatusRecruiting
StartedFebruary 11, 2026
Main results expectedNovember 2026
Study endsNovember 2027
Registry record updatedFebruary 13, 2026
Trial IDNCT07143279 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult men (≥18 years) in best supportive care with documented low total testosterone (<231 ng/dL), who are able to consent and who have no further anti-cancer treatment planned and decline resuscitation.

Probably not a fit

Patients with untreated prostate cancer, known hypersensitivity to the drug or its excipients (including peanut or soya allergy), or those with extremely limited life expectancy who cannot complete treatment may not receive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, single-arm early-phase pilot enrolling adult men with documented hypogonadism (total testosterone < 231 ng/dL) who are receiving best supportive care and have no further therapeutic options. Participants will receive an intramuscular injection of Sustanon 250 (1 mL) on day 0 and then every 15 days, with quality of life measures tracked over the treatment period. Key exclusions include untreated prostate cancer and known hypersensitivity to the product or its excipients, including peanut or soya allergy. The study aims to collect preliminary safety and quality-of-life data to inform larger future trials.

Why it matters

Potential benefit: If successful, regular testosterone supplementation could reduce symptoms of low testosterone and improve overall well-being and quality of life for men in palliative supportive care.

How similar studies have gone: Testosterone replacement has improved symptoms in hypogonadal men in other clinical settings, but its specific use and benefits in patients receiving best supportive/palliative care are less well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male hypogonadal with total testosterone \< 231 ng/dl in best supportive care with no further therapeutic options and who do not wish to be reanimated.
2. Age ≥ 18 years old
3. Patient able to understand the patient information sheet and able to sign the Informed Consent form (ICF) prior to any study related procedure.

Exclusion Criteria:

1. Untreated prostate cancer, given the risk of epiduritis.
2. Known hypersensitivity reactions to the study drug or to any excipients.
3. Known allergies to peanuts or soya.

Where it's running

  • Institut Jules Bordet
    Brussels, Belgium
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.